Hemostatic complications of angiogenesis inhibitors in cancer patients

Tumor vasculature and tumor‐associated neo‐angiogenesis have recently become major targets for rational drug design of antineoplastic agents. Five such agents with angiogenesis inhibiting activity (thalidomide, lenalidomide, bevacizumab, sunitinib, sorafenib) have already obtained US Food and Drug A...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	American journal of hematology 2008-11, Vol.83 (11), p.862-870
Hauptverfasser:	Elice, Francesca, Jacoub, Jack, Rickles, Frederick R., Falanga, Anna, Rodeghiero, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Modulating Agents - adverse effects Anticoagulants - therapeutic use Biological and medical sciences Hematologic and hematopoietic diseases Humans Medical sciences Neoplasms - blood supply Neoplasms - drug therapy Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - physiopathology Thromboembolism - chemically induced Thromboembolism - physiopathology Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!